The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery

NCT ID: NCT06837298

Last Updated: 2025-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-07

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Delayed onset muscle soreness (DOMS) is the result of eccentric muscle contraction and is caused by small tears in the myofibrils. Damage to the muscle fibers causes pain, inflammation, and reduced range of motion which can delay recovery. Peak effects are often experienced 48 - 72 hours following the exercise session but can last up to 7 days post-exercise. Various modalities are utilized to reduce DOMS such as cryotherapy, massage, and compression. However, nutritional supplements have also been studied including Omega 3 fatty acids, creatine monohydrate, tart cherry juice, vitamin D, and probiotics.

A recent study (Kerr, et al., 2023) investigated the effects of a protein supplement (PeptiStrong®) from Vicia faba protein concentrate, a protein derived from Fava bean extract. Results showed that 17 days of 2.4 grams of PeptiStrong® significantly improved muscle strength, reduced muscle fatigue, and reduced myostatin expression during the 72 hour recovery period compared to placebo following a strenuous bout of eccentric exercise. This study aims to repeat the methods of Kerr, et al. with the addition of females and a third experimental group. In addition to 17 days of supplementation with Vicia faba Hydrolysate or placebo, a third group will be given 14 days of placebo followed by 3 days of the Vicia faba Hydrolysate supplement to determine if short-term supplementation results in a similar benefit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Damage Muscle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

PeptiStrong® capsules 2.4 grams per day for 17 days

Group Type PLACEBO_COMPARATOR

Placebo control capsules

Intervention Type OTHER

2.4 grams (g) daily

PeptiStrong® 17 days

PeptiStrong® capsules 2.4 grams/day for 17 days

Group Type EXPERIMENTAL

PeptiStrong® supplement capsules with same appearance as placebo capsules

Intervention Type OTHER

2.4 g daily

PeptiStrong® 3 days

14 days of Placebo followed by 3 days of PeptiStrong®

Group Type EXPERIMENTAL

PeptiStrong® supplement capsules following muscle damaging exercise on Day 14

Intervention Type OTHER

2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo control capsules

2.4 grams (g) daily

Intervention Type OTHER

PeptiStrong® supplement capsules with same appearance as placebo capsules

2.4 g daily

Intervention Type OTHER

PeptiStrong® supplement capsules following muscle damaging exercise on Day 14

2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females 18 - 45 years of age.
* Willing to fast overnight on the 4 testing occasions.
* Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA).
* Moderately active (exercise 3-5 days per week)
* Fluent in reading, writing, and speaking English
* Participants agree to maintain their normal diet and perform only light to moderate exercise for the duration of the study.
* BMI between 18.5 and 29.9 kg/m2
* Participants agree to refrain from consuming alcohol in the 48 hours leading up to a test day.
* Willingness to complete questionnaires, records and diaries associated with the study and to complete all lab visits.
* Refrain from any exercise from 48 hours prior to each test or blood draw.
* Healthy as determined by General Health Questionnaire.
* Non-smoker

Exclusion Criteria

* Individuals that are glucose-6-phosphate-dehydrogenase deficient. The test product in this study contains fava bean extract which may produce favism in genetically susceptible individuals.
* Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives)
* Pregnant or nursing or planning to become pregnant.
* Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months
* Volunteers with unstable medical conditions.
* Any complaints that could interfere with the ability to exercise.
* Individuals who are cognitively impaired or unable to give informed consent.
* Any co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g. arthritis, spasticity / rigidity, all neurological disorders, paralysis).
* Creatine supplements, corticosteroids, NSAIDS, amino acids, injectible peptides, collagen, and nicotinamide (Vit B3/niacin).
* Presence or history of neurological disorders or significant psychiatric illness.
* Any condition the study investigator believes would interfere with eligibility following the study protocol, effect the study results, or put the subject at undue risk.
* Participation in resistance or aerobic exercise within 48 hours of the test days.
* Participation of \>3 high-intensity exercise sessions per week.
* Undertake recovery methods such as sea swims, foam rolling, cryotherapy or excessive stretching during days 14-17.
* Have been in contact with a suspected or confirmed case of COVID-19 in previous 14 days.
* Are Hepatitis A- or B-positive or have had a sexual partner infected with hepatitis or HIV and not taking medication.
* Are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If you are unsure if a company would be considered a competitor to Gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before ou sign the informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PepsiCo Global R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kris Osterberg, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

PepsiCo R&D Life Sciences, Sports Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gatorade Sports Science Institute at IMG Academy

Bradenton, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kris Osterberg, PhD, RD

Role: CONTACT

847.707.3118

Brandon Shepherd, MS

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kris Osterberg, PhD, RD

Role: primary

847-707-3118

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEP-2414

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.